ANGES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 47 JPY | +2.17% |
|
-4.08% | -34.72% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 67M 430K 586K | Sales 2023 | 152M 976K 1.33M | Capitalization | 14.23B 91.39M 124M |
|---|---|---|---|---|---|
| Net income 2022 | -14.71B -94.51M -129M | Net income 2023 | -7.44B -47.77M -64.99M | EV / Sales 2022 | 165 x |
| Net cash position 2022 | 9.88B 63.47M 86.35M | Net cash position 2023 | 3.8B 24.4M 33.2M | EV / Sales 2023 | 68.6 x |
| P/E ratio 2022 |
-1.29
x | P/E ratio 2023 |
-1.83
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 96.97% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +2.17% | ||
| 1 week | -4.08% | ||
| Current month | -4.08% | ||
| 1 month | -7.84% | ||
| 3 months | -33.80% | ||
| 6 months | -43.37% | ||
| Current year | -34.72% |
1 week
46.00
49.00
1 month
46.0052.00
Current year
46.0092.00
1 year
46.00143.00
3 years
46.001 060.00
5 years
46.002 492.00
10 years
46.002 492.00
| Managers | Title | Age | Since |
|---|---|---|---|
Tetsuji Yoneo
DFI | Director of Finance/CFO | 54 | 12-09-30 |
Ei Yamada
PSD | President | 73 | 01-04-30 |
Kazuo Suzuki
CTO | Chief Tech/Sci/R&D Officer | 67 | 19-01-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ei Yamada
PSD | President | 73 | 01-04-30 |
Makoto Hara
BRD | Director/Board Member | 73 | 18-03-28 |
Junichi Komamura
BRD | Director/Board Member | 74 | 12-02-29 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-17 | 47 | +2.17% | 408,600 |
| 24-05-16 | 46 | 0.00% | 315,100 |
| 24-05-15 | 46 | -2.13% | 595,700 |
| 24-05-14 | 47 | +2.17% | 803,200 |
| 24-05-13 | 46 | -6.12% | 2,202,300 |
Delayed Quote Japan Exchange, May 17, 2024 at 02:00 am
More quotes
AnGes, Inc., formerly AnGes MG, Inc., is a Japan-based company mainly engaged in the development of genetic medicines. The Company is involved in the development of hepatocyte growth factor (HGF) genetic medicines, NF-KB decoy oligo and hemagglutinating virus of Japan envelope (HVJ-E) non-viral vector, among others. As of December 31, 2012, the Company had four consolidated subsidiaries. On January 31, 2013, the Company sold a 95.3% stake of a Osaka-based subsidiary to ISHIHARA SANGYO KAISHA LTD.
Calendar
2024-07-31
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -34.72% | 65.82M | |
| +9.42% | 115B | |
| +11.84% | 106B | |
| -14.15% | 21.84B | |
| -1.05% | 21.96B | |
| -5.29% | 19.21B | |
| -38.29% | 17.71B | |
| -4.16% | 18.08B | |
| +7.99% | 14.32B | |
| +36.24% | 12.42B |
- Stock Market
- Equities
- 4563 Stock
